Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin in CF patients with Burkholderia cepacia complex
NCT00298922Phase 2Unknown
- Sponsor
- Unity Health Toronto
- Start
- Feb 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Azithromycin with Placebo (2 arms). Primary endpoints: Change in FEV1 in % predicted at 24 weeks, Adverse events at 24 weeks and 1 more. Status: unknown.
02
Drugs
azithromycin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00298922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298922.